Free Trial

Evotec (EVO) Competitors

Evotec logo
$3.67 -0.08 (-2.13%)
Closing price 09/23/2025 04:00 PM Eastern
Extended Trading
$3.61 -0.06 (-1.66%)
As of 05:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EVO vs. PTCT, MENS, ACLX, PCVX, KRYS, ARWR, ACAD, ADMA, AAPG, and MTSR

Should you be buying Evotec stock or one of its competitors? The main competitors of Evotec include PTC Therapeutics (PTCT), Jyong Biotech (MENS), Arcellx (ACLX), Vaxcyte (PCVX), Krystal Biotech (KRYS), Arrowhead Pharmaceuticals (ARWR), ACADIA Pharmaceuticals (ACAD), ADMA Biologics (ADMA), Ascentage Pharma Group International (AAPG), and Metsera (MTSR). These companies are all part of the "pharmaceutical products" industry.

Evotec vs. Its Competitors

PTC Therapeutics (NASDAQ:PTCT) and Evotec (NASDAQ:EVO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

5.8% of Evotec shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, PTC Therapeutics had 3 more articles in the media than Evotec. MarketBeat recorded 6 mentions for PTC Therapeutics and 3 mentions for Evotec. PTC Therapeutics' average media sentiment score of 1.27 beat Evotec's score of 0.88 indicating that PTC Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PTC Therapeutics
5 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Evotec
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

PTC Therapeutics currently has a consensus price target of $69.00, suggesting a potential upside of 13.94%. Evotec has a consensus price target of $5.40, suggesting a potential upside of 47.14%. Given Evotec's higher probable upside, analysts plainly believe Evotec is more favorable than PTC Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PTC Therapeutics
1 Sell rating(s)
5 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.53
Evotec
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50

PTC Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Evotec has a beta of 1.72, suggesting that its stock price is 72% more volatile than the S&P 500.

PTC Therapeutics has a net margin of 35.65% compared to Evotec's net margin of -20.14%. Evotec's return on equity of -16.94% beat PTC Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
PTC Therapeutics35.65% -106.31% 30.61%
Evotec -20.14%-16.94%-8.14%

Evotec has higher revenue and earnings than PTC Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PTC Therapeutics$806.78M5.96-$363.30M$6.978.69
Evotec$862.40M1.51-$212.18MN/AN/A

Summary

PTC Therapeutics beats Evotec on 8 of the 14 factors compared between the two stocks.

Get Evotec News Delivered to You Automatically

Sign up to receive the latest news and ratings for EVO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EVO vs. The Competition

MetricEvotecMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.33B$2.55B$5.76B$10.50B
Dividend YieldN/A53.63%5.53%4.57%
P/E RatioN/A23.4075.9626.62
Price / Sales1.51513.39473.7891.77
Price / CashN/A171.0137.4661.85
Price / Book1.265.3813.486.45
Net Income-$212.18M$32.95M$3.29B$271.57M
7 Day Performance0.82%3.00%1.83%2.61%
1 Month Performance0.82%4.89%4.00%7.28%
1 Year Performance9.55%0.71%75.89%29.60%

Evotec Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EVO
Evotec
1.7496 of 5 stars
$3.67
-2.1%
$5.40
+47.1%
+12.2%$1.33B$862.40M0.004,827News Coverage
Gap Down
PTCT
PTC Therapeutics
3.8011 of 5 stars
$58.98
-3.5%
$69.00
+17.0%
+64.8%$4.85B$806.78M8.461,410Positive News
MENS
Jyong Biotech
N/A$51.82
-15.7%
N/AN/A$4.68BN/A0.0031High Trading Volume
ACLX
Arcellx
2.3083 of 5 stars
$75.20
-1.3%
$114.31
+52.0%
-7.9%$4.23B$107.94M-21.9980Positive News
PCVX
Vaxcyte
2.0796 of 5 stars
$31.00
-3.6%
$106.25
+242.7%
-70.4%$4.18BN/A-7.54160Positive News
KRYS
Krystal Biotech
4.9356 of 5 stars
$155.71
+8.4%
$209.00
+34.2%
-8.4%$4.16B$359.21M31.65210High Trading Volume
ARWR
Arrowhead Pharmaceuticals
4.217 of 5 stars
$28.67
-3.5%
$43.14
+50.5%
+62.5%$4.11B$3.55M-22.40400
ACAD
ACADIA Pharmaceuticals
4.3946 of 5 stars
$24.67
+4.5%
$29.65
+20.2%
+44.9%$3.98B$957.80M18.55510
ADMA
ADMA Biologics
3.3084 of 5 stars
$15.30
-5.0%
$27.67
+80.8%
-20.2%$3.84B$426.45M17.79530Positive News
AAPG
Ascentage Pharma Group International
N/A$38.63
-4.5%
N/AN/A$3.77B$134.35M0.00600
MTSR
Metsera
N/A$34.21
-4.1%
$63.50
+85.6%
N/A$3.75BN/A0.0081Trending News
Analyst Downgrade

Related Companies and Tools


This page (NASDAQ:EVO) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners